- Main
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
- Ettinger, David S;
- Wood, Douglas E;
- Akerley, Wallace;
- Bazhenova, Lyudmila A;
- Borghaei, Hossein;
- Camidge, David Ross;
- Cheney, Richard T;
- Chirieac, Lucian R;
- D'Amico, Thomas A;
- Dilling, Thomas J;
- Dobelbower, M Chris;
- Govindan, Ramaswamy;
- Hennon, Mark;
- Horn, Leora;
- Jahan, Thierry M;
- Komaki, Ritsuko;
- Lackner, Rudy P;
- Lanuti, Michael;
- Lilenbaum, Rogerio;
- Lin, Jules;
- Loo, Billy W;
- Martins, Renato;
- Otterson, Gregory A;
- Patel, Jyoti D;
- Pisters, Katherine M;
- Reckamp, Karen;
- Riely, Gregory J;
- Schild, Steven E;
- Shapiro, Theresa A;
- Sharma, Neelesh;
- Stevenson, James;
- Swanson, Scott J;
- Tauer, Kurt;
- Yang, Stephen C;
- Gregory, Kristina;
- Hughes, Miranda
- et al.
Published Web Location
https://doi.org/10.6004/jnccn.2016.0031Abstract
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-